Atypical antipsychotic drugs, schizophrenia, and metabolic syndrome in non-euro-american societies

Clinical Neuropharmacology

Volumn 35, Issue 3, 2012, Pages 141-147

  Bou Khalil, Rami ^a,b  

^a Psychiatric Hospital of the Cross   (Lebanon)

^b SAINT JOSEPH UNIVERSITY   (Lebanon)

Author keywords

Asia; atypical antipsychotic drugs; Australia; metabolic syndrome; schizophrenia; South America

Indexed keywords

ADIPONECTIN; AMISULPRIDE; ARIPIPRAZOLE; ASENAPINE; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; CHLORPROMAZINE; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; HIGH DENSITY LIPOPROTEIN; ILOPERIDONE; LEVOMEPROMAZINE; LITHIUM; LURASIDONE; OLANZAPINE; PALIPERIDONE; PEROSPIRONE; PIMOZIDE; QUETIAPINE; RISPERIDONE; SULPIRIDE; THIORIDAZINE; TRIACYLGLYCEROL; VALPROIC ACID; ZIPRASIDONE; ZOTEPINE; ZUCLOPENTHIXOL;

ASIA; AUSTRALIA; BODY MASS; CROSS-SECTIONAL STUDY; DYSLIPIDEMIA; EUROPEAN AMERICAN; FAMILY HISTORY; FOLLOW UP; GLUCOSE INTOLERANCE; HIGH RISK POPULATION; HUMAN; INCIDENCE; INSULIN RESISTANCE; LIPOPROTEIN BLOOD LEVEL; MEDLINE; METABOLIC SYNDROME X; NORTH AMERICA; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SENESCENCE; SEX DIFFERENCE; SOUTH AMERICA; SYSTEMATIC REVIEW; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; CROSS-SECTIONAL STUDIES; HUMANS; METABOLIC SYNDROME X; PROSPECTIVE STUDIES; SCHIZOPHRENIA; UNITED STATES;

EID: 84861515314     PISSN: 03625664     EISSN: 1537162X     Source Type: Journal    
DOI: 10.1097/WNF.0b013e31824d5288     Document Type: Review

References (49)

1. Bushe C, Holt R. Prevalence of diabetes and glucose intolerance in patients with schizophrenia. Br J Psychiatry 2004;184:67Y71.
2. McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005;80:19Y32.
3. Koller E, Schneider B, Bennett K, et al. Clozapine-associated diabetes. Am J Med 2001;111:716Y723.
4. Koller EA, Doraiswamy PM. Olanzapine-associated diabetes mellitus. Pharmacotherapy 2002;22:841Y852.
5. Koller EA, Cross JT, Doraiswamy PM, et al. Risperidone-associated diabetes mellitus: a pharmacovigilance study. Pharmacotherapy 2003;23:735Y744.
6. Lindenmayer JP, Czobor P, Volavka J, et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 2003;160:290Y296.
7. Howes OD, Bhatnagar A, Gaughran FP, et al. A prospective study of impairment in glucose control caused by clozapine without changes in insulin resistance. Am J Psychiatry 2004;161:361Y363.
8. Su KP, Wu PL, Pariante CM. A crossover study on lipid and weight changes associated with olanzapine and risperidone. Psychopharmacology (Berl) 2005;183:383Y386.
9. Sowell MO, Mukhopadhyay N, Cavazzoni P, et al. Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo. J Clin Endocrinol Metab 2002;87:2918Y2923.
10. Ananth J, Kolli S, Gunatilake S, et al. Atypical antipsychotic drugs, diabetes and ethnicity. Expert Opin Drug Saf 2005;4:1111Y1124.
11. Templeman LA, Reynolds GP, Arranz B, et al. Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. Pharmacogenet Genomics 2005;15:195Y200.
12. Reynolds GP, Zhang Z, Zhang X. Polymorphism of the promoter region of the serotonin 5-HT(2C) receptor gene and clozapine-induced weight gain. Am J Psychiatry 2003;160:677Y679.
13. Lane HY, Liu YC, Huang CL, et al. Risperidone-related weight gain: genetic and nongenetic predictors. J Clin Psychopharmacol 2006;26:128Y134.
14. Saddichha S, Ameen S, Akhtar S. Incidence of new onset metabolic syndrome with atypical antipsychotics in first episode schizophrenia: a six-week prospective study in Indian female patients. Schizophr Res 2007;95:247.
15. Saddichha S, Manjunatha N, Ameen S, et al. Metabolic syndrome in first episode schizophreniaVa randomized double-blind controlled, short-term prospective study. Schizophr Res 2008;101:266Y272.
16. Srisurapanont M, Likhitsathian S, Boonyanaruthee V, et al. Metabolic syndrome in Thai schizophrenic patients: a naturalistic one-year follow-up study. BMC Psychiatry 2007;7:14.
17. Bai YM, Chen JY, Yang WS, et al. Adiponectin as a potential biomarker for the metabolic syndrome in Chinese patients taking clozapine for schizophrenia. J Clin Psychiatry 2007;68:1834Y1839.
18. Bai YM, Chen TT, Yang WS, et al. Association of adiponectin and metabolic syndrome among patients taking atypical antipsychotics for schizophrenia: a cohort study. Schizophr Res 2009;111:1Y8.
19. Lee E, Leung CM. Atypical antipsychotics and metabolic outcomes in Chinese patients: a comparison of olanzapine and risperidone. J Clin Psychopharmacol 2008;28:707Y709.
20. Huang MC, Lu ML, Tsai CJ, et al. Prevalence of metabolic syndrome among patients with schizophrenia or schizoaffective disorder in Taiwan. Acta Psychiatr Scand 2009;120:274Y280.
21. Sugawara N, Yasui-Furukori N, Sato Y, et al. Prevalence of metabolic syndrome among patients with schizophrenia in Japan. Schizophr Res 2010;123:244Y250.
22. Rezaei O, Khodaie-Ardakani MR, Mandegar MH, et al. Prevalence of metabolic syndrome among an Iranian cohort of inpatients with schizophrenia. Int J Psychiatry Med 2009;39:451Y462.
23. Yazici MK, Anil Yaciolu AE, Erturul A, et al. The prevalence and clinical correlates of metabolic syndrome in patients with schizophrenia: findings from a cohort in Turkey. Eur Arch Psychiatry Clin Neurosci 2011;261:69Y78.
24. Cerit C, Ozten E, Yildiz M. The prevalence of metabolic syndrome and related factors in patients with schizophrenia. Turk Psikiyatri Derg 2008;19:124Y132.
25. Boke O, Aker S, Sarisoy G, et al. Prevalence of metabolic syndrome among inpatients with schizophrenia. Int J Psychiatry Med 2008;38:103Y112.
26. Teixeira PJ, Rocha FL. The prevalence of metabolic syndrome among psychiatric inpatients in Brazil. Rev Bras Psiquiatr 2007;29:330Y336.
27. Tirupati S, Chua LE. Body mass index as a screening test for metabolic syndrome in schizophrenia and schizoaffective disorders. Australas Psychiatry 2007;15:470Y473.
28. Brunero S, Lamont S, Fairbrother G. Prevalence and predictors of metabolic syndrome among patients attending an outpatient clozapine clinic in Australia. Arch Psychiatr Nurs 2009;23:261Y268.
29. John AP, Koloth R, Dragovic M, et al. Prevalence of metabolic syndrome among Australians with severe mental illness. Med J Aust 2009;190:176Y179.
30. Expert Panel on Detection and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486Y2497.
31. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement (executive summary). Circulation 2005;112:2735Y2752.
32. Alberti KGMM, Zimmet P, Shaw J. Metabolic syndromeVa new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet Med 2005;23:469Y480.
33. Sugawara N, Yasui-Furukori N, Sato Y, et al. Comparison of prevalence of metabolic syndrome in hospital and community-based Japanese patients with schizophrenia. Ann Gen Psychiatry 2011;10(1):21.
34. Pan WH, Yeh WT, Weng LC. Epidemiology of metabolic syndrome in Asia. Asia Pac J Clin Nutr 2008;17(Suppl 1):37Y42.
35. Misra A, Khurana L. Obesity and the metabolic syndrome in developing countries. J Clin Endocrinol Metab 2008;93(11 Suppl 1):S9YS30.
36. Márquez-Sandoval F, Macedo-Ojeda G, Viramontes-Hö rner D, et al. The prevalence of metabolic syndrome in Latin America: a systematic review. Public Health Nutr 2011;14(10):1702Y1713.
37. Schutte AE, Shemesh T, Rowley K, et al. The metabolic syndrome and changing relationship between blood pressure and insulin with age, as observed in Aboriginal and Torres Strait Islander peoples. Diabet Med 2005;22(11):1589Y1597.
38. Spalding A, Kernan J, Lockette W. The metabolic syndrome: a modern plague spread by modern technology. J Clin Hypertens (Greenwich) 2009;11:755Y760.
39. Onat A. Metabolic syndrome: nature, therapeutic solutions and options. Expert Opin Pharmacother 2011;12:1887Y1900.
40. Beavers KM, Nicklas BJ. Effects of lifestyle interventions on inflammatory markers in the metabolic syndrome. Front Biosci (Schol Ed) 2011;3:168Y177.
41. Misra A, Khurana L. Obesity-related non-communicable diseases: south Asians vs white Caucasians. Int J Obes (Lond) 2011;35:167Y187.
42. Monda KL, North KE, Hunt SC, et al. The genetics of obesity and the metabolic syndrome. Endocr Metab Immune Disord Drug Targets 2010;10:86Y108.
43. Amuna P, Zotor FB. Epidemiological and nutrition transition in developing countries: impact on human health and development. Proc Nutr Soc 2008;67:82Y90.
44. Tada N, Maruyama C, Koba S, et al. Japanese dietary lifestyle and cardiovascular disease. J Atheroscler Thromb 2011;18:723Y734.
45. Hu FB, Liu Y, Willett WC. Preventing chronic diseases by promoting healthy diet and lifestyle: public policy implications for China. Obes Rev 2011;12:552Y559.
46. Isharwal S, Misra A,Wasir JS, et al. Diet and insulin resistance: a review and Asian Indian perspective. Indian J Med Res 2009;129:485Y499.
47. Misra A, Misra R, Wijesuriya M, et al. The metabolic syndrome in South Asians: continuing escalation and possible solutions. Indian J Med Res 2007;125:345Y354.
48. Alberti KG, Zimmet P, Shaw J, et al. The metabolic syndromeVa new worldwide definition. Lancet 2005;366:1059Y1062.
49. Khader Y, Bateiha A, El-Khateeb M, et al. High prevalence of the metabolic syndrome among Northern Jordanians. J Diabetes Complications 2007;21:214Y219.